| Coronary heart disease

Xarelto vs Norliqva

Side-by-side clinical, coverage, and cost comparison for coronary heart disease.

Deep comparison between: Xarelto vs Norliqva with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsNorliqva has a higher rate of injection site reactions vs Xarelto based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Norliqva but not Xarelto, including UnitedHealthcare

Category

Xarelto

Norliqva

At A Glance

RouteOral

FrequencyOnce or twice daily

ClassFactor Xa inhibitor

RouteOral

FrequencyDaily

ClassCalcium channel blocker

Indications

Atrial Fibrillation
Deep Vein Thrombosis
Pulmonary Embolism
Venous Thrombosis
Coronary heart disease
Peripheral Arterial Diseases

Hypertensive disease
Stable angina
Coronary heart disease

Dosing

Atrial Fibrillation 20 mg once daily with evening meal (CrCl >50 mL/min); 15 mg once daily with evening meal (CrCl <=50 mL/min), oral.

Deep Vein Thrombosis, Pulmonary Embolism 15 mg twice daily with food for 21 days, then 20 mg once daily with food for remaining treatment, oral.

Venous Thrombosis 10 mg once daily with or without food: for recurrence prevention after at least 6 months of standard anticoagulant treatment; or 35 days post-hip replacement surgery; or 12 days post-knee replacement surgery; or 31-39 days total for prophylaxis in acutely ill medical patients, oral.

Coronary heart disease, Peripheral Arterial Diseases 2.5 mg twice daily with or without food, in combination with aspirin 75-100 mg once daily, oral.

Hypertensive disease Adults: 5 mg orally once daily (max 10 mg); small, fragile, elderly, or hepatic insufficiency patients start at 2.5 mg once daily; pediatric patients (>=6 years): 2.5-5 mg orally once daily.

Stable angina 5-10 mg orally once daily; most patients require 10 mg for adequate effect.

Coronary heart disease 5-10 mg orally once daily; majority of patients in clinical studies required 10 mg.

Contraindications

Active pathological bleeding
Severe hypersensitivity reaction to rivaroxaban or any excipient (e.g., anaphylactic reactions)

Known sensitivity to amlodipine

Drug Interactions

1272View drug interactions

1162View drug interactions

Adverse Reactions

Most common Bleeding complications, wound secretion, pruritus, back pain, abdominal pain, muscle spasm, dizziness, fatigue

Serious Intracranial hemorrhage, gastrointestinal bleeding, fatal bleeding, spinal/epidural hematoma

Postmarketing Agranulocytosis, thrombocytopenia, jaundice, cholestasis, hepatitis, hypersensitivity, anaphylactic reaction, anaphylactic shock, angioedema, hemiparesis, anticoagulant-related nephropathy, eosinophilic pneumonia, Stevens-Johnson syndrome, DRESS, atraumatic splenic rupture

Most common (>1%) Edema, dizziness, flushing, palpitation, fatigue, nausea.

Postmarketing Gynecomastia, jaundice, hepatic enzyme elevations, extrapyramidal disorder.

Pharmacology

Rivaroxaban is a selective oral Factor Xa (FXa) inhibitor that does not require a cofactor for activity; by inhibiting free FXa and prothrombinase activity, it decreases thrombin generation and indirectly inhibits thrombin-induced platelet aggregation.

Amlodipine is a dihydropyridine calcium channel blocker that inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, acting as a peripheral arterial vasodilator to reduce peripheral vascular resistance and blood pressure, and relieving angina by reducing myocardial oxygen demand and blocking coronary vasospasm.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Xarelto